Frontlight ResearchEarly access
Metastatic breast cancer trials in Italy
70 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 2Not yet taking people in ItalyA TWO-STAGE, SINGLE-ARM, PHASE II STUDY OF ZONGERTINIB PLUS FULVESTRANT IN PARTICIPANTS WITH HORMONE RECEPTOR-POSITIVE/HER2- NEGATIVE ADVANCED BREAST CANCER HARBORING HER2 MUTATIONS (AGATHA)
- Where
- Florence, Milan, Naples, Rome
- Age
- 18 years and over
- People
- 25 worldwide
- Run by
- Medica Scientia Innovation Research S.L.
See details and how to join2026-525328-10-00 - Phase 3Taking peopleA Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
- Where
- Aviano, Florence, Meldola, Milan, Naples, Rome
- Age
- 18 years and over
- People
- 100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07205822 · EU 2025-521904-23-00 - Phase 1/2Not yet taking people in ItalyA Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
- Where
- Aviano, Meldola, Milan, Monza, Padova, Pisa
- Age
- 18 years and over
- People
- 220 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT07701941 · EU 2024-517541-14-00 - Phase 3Taking peoplePalazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Where
- Aviano, Bergamo, Bologna, Genoa, Lecce, Milan, Monza, Naples, Padova, Pisa, Prato, Rome, Rozzano
- Age
- 18 years and over
- People
- 1,000 worldwide
- Run by
- Olema Pharmaceuticals, Inc.
See details and how to joinNCT07085767 · EU 2025-522873-12-00 - Phase 3Taking peopleStereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer
- Where
- Florence, Milan
- Age
- 18 years and over
- People
- 345 worldwide
- Run by
- Vastra Gotaland Region
See details and how to joinNCT05377047 - Phase 2Not yet taking people in ItalyRoll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.
- Where
- Milan, Padova
- People
- 51 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07679269 · EU 2026-525890-38-00 - No phaseTaking peopleTo Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer
- Where
- Prato
- People
- 150
- Run by
- Fondazione Sandro Pitigliani
See details and how to joinNCT04660435 - No phaseTaking peopleEORTC Metastatic Breast Cancer Module Development
- Where
- Naples, Padova
- Age
- 18 years and over
- People
- 568 worldwide
- Run by
- University of Leeds
See details and how to joinNCT07806266 - Phase 2Not yet taking people in ItalyLuMIERE: A Phase 1/2, Multicenter, Open label, Non randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of [177Lu]Lu-FAP-2286 in Participants with an Advanced Solid Tumor
- Where
- Meldola, Milan, Naples, Negrar, Reggio Emilia
- Age
- 18 years and over
- People
- 36 worldwide
- Run by
- Novartis Pharma AG
See details and how to joinNCT04939610 · EU 2023-508995-12-01 - Phase 1/2Taking peopleStudy of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
- Where
- Milan, Modena, Naples
- Age
- 18 years to 100 years
- People
- 280 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06726148 · EU 2024-517281-42-00 - Phase 3Taking peopleElacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
- Where
- Bergamo, Florence, Genoa, Leghorn, Milan, Modena, Monserrato, Monza, Naples, Negrar, Novara, Piacenza, Rome
- Age
- 18 years and over
- People
- 300 worldwide
- Run by
- MedSIR
See details and how to joinNCT06382948 · EU 2024-512926-27-00 - No phaseActive, not recruitingDESTINY Breast Respond HER2-(Ultra)Low Europe
- Where
- Alessandria, Chieti, Città di Castello, Empoli, Lecce, Lecco, Legnago, Legnano, Meldola, Modena, Monza, Naples, Novara, Padova, Palermo, Pavia, Pisa, Potenza, Province of Macerata, Reggio Calabria, Reggio Emilia, Roma, Salerno, San Giovanni Rotondo, Sassari, Taormina, Torino, Treviso, Udine, Varese
- Age
- 18 years and over
- People
- 2,295 worldwide
- Run by
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
See details and how to joinNCT05945732 - No phaseCompletedAURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.
- Where
- Biella, Bolzano, Carpi, Genova, Legnago, Milan, Parma, Pavia, Reggio Emilia
- Age
- 18 years and over
- People
- 1,000 worldwide
- Run by
- Jules Bordet Institute
See details and how to joinNCT02102165 - Phase 2Taking peopleSafety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
- Where
- Ancona, Aviano, Florence, Genoa, Macerata, Milan, Modena, Monza, Naples, Negrar, Novara, Padova, Piacenza, Rome
- Age
- 18 years and over
- People
- 200 worldwide
- Run by
- MedSIR
See details and how to joinNCT06486883 · EU 2024-512360-55-00 - Phase 1/2Taking peopleFirst-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Where
- Alexandria, Brescia, Milan, Monza, Pisa, Ravenna, Rome, Verona
- Age
- 18 years and over
- People
- 880 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT05768139 · EU 2023-504807-94-00 - Phase 1Taking peopleFirst-in-Human Study of OKI-219 Alone and in Combination with Other Therapies in Patients with Solid Tumors / Breast Cancer
- Where
- Milan, Monza, Rozzano
- Age
- 18 years and over
- People
- 145 worldwide
- Run by
- Onkure Inc.
See details and how to join2023-508435-31-00 - Phase 2Taking people“A Phase II trial of atezolizumab plus CArboplatin plus nab-Paclitaxel as first-line Therapy in metastatic triple-negative PD-L1 positive breast cancer patients”
- Where
- Avellino, Aviano, Bologna, Cuneo, Faenza, Genoa, Meldola, Naples, Parma, Pozzuoli, Reggio Emilia, Rimini, Roma, Terni, Turin, Vicenza, Ospedale S. Timoteo di Termoli
- Age
- 18 years and over
- People
- 104
- Run by
- Consorzio Oncotech
See details and how to join2024-519514-31-00 - Phase 2Taking peopleA Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
- Where
- Cremona
- Age
- 18 years and over
- People
- 37 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT04641247 · EU 2023-506618-29-00 - No phaseTaking peopleEmotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
- Where
- Ancona, Aviano, Bagno a Ripoli, Bari, Bergamo, Brescia, Brindisi, Busto Arsizio, Como, Florence, Genova, Messina, Milan, Modena, Naples, Novara, Palermo, Pavia, Pisa, Prato, Rimini, Roma, Rome, Sassari, Verduno, Verona, Vimercate
- Age
- 18 years and over
- People
- 1,000
- Run by
- European Institute of Oncology
See details and how to joinNCT06994377 - Phase 3Active, not recruitingTrastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
- Where
- Bari, Bologna, Genoa, Milan, Misterbianco, Naples, Padova, Prato, Rome, Trento
- Age
- 18 years and over
- People
- 250 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT05950945 · EU 2023-505616-38-00 - Phase 1/2Taking peopleBeamion BCGC-1: A study to find a suitable dose of zongertinib used alone and in combination with other treatments to test whether it helps people with different types of HER2+ cancer that has spread
- Where
- Ancona, Candiolo, Meldola, Milan, Misterbianco, Naples, Rozzano
- Age
- 18 years and over
- People
- 181 worldwide
- Run by
- Boehringer Ingelheim International GmbH
See details and how to join2023-509566-38-00 - Phase 1/2Taking peopleStudy of GVV858 as a single agent or in combination with endocrine therapy in patients with HR+/HER2- breast cancer and other advanced solid tumors
- Where
- Milan
- Age
- 18 years and over
- People
- 55 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-521911-38-00 - Phase 2Taking peopleElacestrant and Exemestane for Patients With Pretreated HR+/HER2- Metastatic Breast Cancer and [18F] FES-avid Lesions (COMBINE)
- Where
- Milan
- Age
- 18 years and over
- People
- 26
- Run by
- European Institute of Oncology
See details and how to joinNCT07395336 - Phase 1Taking peoplePhase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.
- Where
- Milan, Reggio Emilia
- Age
- 18 years and over
- People
- 76 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2023-510356-23-00 - Phase 2Not yet taking people in ItalyA multicenter, multicohort, phase 2 platform trial to personalize second-line treatment intensity and targeting in HR-positive, HER2-negative metastatic breast cancer through an integrated liquid biopsy algorithm.
- Where
- Aviano, Meldola, Misterbianco, Rome, Vicenza
- Age
- 18 years and over
- People
- 159
- Run by
- Centro Di Riferimento Oncologico Di Aviano
See details and how to join2025-523460-21-00